| BIOCRYST PHARMACEUTICALS |
| USA |
| Gesundheit |
| US09058V1035 / 896047 |
| BO1 (Frankfurt) / BCRX (NASDAQ) |
| FRA:BO1, ETR:BO1, BO1:GR, NASDAQ:BCRX |
| - |
| https://www.biocryst.com/ |
|
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for rare diseases, with a primary emphasis on hereditary angioedema (HAE). Its commercial portfolio is centered on ORLADEYO, an oral therapy..
>Volltext.. |
| 1931.21 Mio. EUR |
| 2354.34 Mio. EUR |
| 818.97 Mio. EUR |
| 336.87 Mio. EUR |
| -334.93 Mio. EUR |
| -1.26 EUR |
| 728.45 Mio. EUR |
| 135.35 Mio. EUR |
| 312.57 Mio. EUR |
| 1.69 |
| 74.03% |
| -1011.07% |
| - |
| - |
| - |
| - |
| BIOCRYST |
| 22.09.26 |
|
||||
|